About StrideBio
StrideBio is a company based in Durham (United States) founded in 2015. StrideBio has raised $98.2 million across 3 funding rounds from investors including ARE, Takeda Pharmaceuticals and Sarepta Therapeutics. The company has 109 employees as of December 31, 2022. StrideBio offers products and services including STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline. StrideBio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Durham, United States
- Employees 109 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stridebio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$98.2 M (USD)
in 3 rounds
-
Latest Funding Round
$81.5 M (USD), Series B
Mar 16, 2021
-
Investors
ARE
& 11 more
-
Employee Count
109
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of StrideBio
StrideBio offers a comprehensive portfolio of products and services, including STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline.
Platform for developing advanced gene therapies.
Service for producing AAV vectors used in gene therapy.
Pipeline of gene therapies targeting life-threatening diseases.
People of StrideBio
Unlock access to complete
Unlock access to complete
Funding Insights of StrideBio
StrideBio has successfully raised a total of $98.2M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $81.5 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in StrideBio
StrideBio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Takeda Pharmaceuticals and Sarepta Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Locked | Locked | Locked |
Investor details for StrideBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by StrideBio
Investment portfolio details for StrideBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - StrideBio
Detailed financials for StrideBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stridebio Comparisons
Peer comparison for StrideBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of StrideBio
StrideBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
Detailed competitors of StrideBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stridebio
Complete news archive for StrideBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about StrideBio
StrideBio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
StrideBio is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
StrideBio is a funded company, having raised a total of $98.2M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at StrideBio is 109.
Founded in 2015 and headquartered in Durham, United States, AAV-based gene therapies for rare diseases are developed within the biotechnology sector. Therapies are targeted at conditions including Friedreichs ataxia, Niemann-Pick disease type C, Angelman syndrome, Dravet syndrome, and Rett syndrome. Operations rely on a structure-inspired adeno-associated virus vector engineering platform to advance treatment options.
StrideBio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
StrideBio offers STRIVE Capsid Platform, AAV Manufacturing, and Therapeutic Pipeline.
StrideBio has 12 investors. Key investors include ARE, Takeda Pharmaceuticals, Sarepta Therapeutics, Novo Holdings, and Pontifax Venture Capital.